Submitted by Anonymous (not verified) on 17 October 2025 - 10:20
Opinion/decision on a Paediatric investigation plan (PIP): Darzalex, Daratumumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0339/2024
Source: